Table II.
Estimates of the level of dA-AL-I in frozen and FFPE kidney tissue of human patients with upper urothelial tract cancer
| Subject | Tissue | 32P-postlabeling | LC-MS/MS3 | DNA yielda (μg) | Surface area (cm2)b | Year, procured |
|---|---|---|---|---|---|---|
| (adducts per 108 DNA bases) | ||||||
| 1 | FR | 3.2 | 2.7±0.1 | |||
| FFPE | 1.8 | 2.1 | 1.6 | 2007 | ||
| 2 | FR | 2.2 | 3.9±0.1 | |||
| FFPE | 3.8±0.1 | 6.8 | 1.5 | 2008 | ||
| 3 | FR | 1.1 | 2.2±0.0 | |||
| FFPE | 3.5 | 3.5 | 2.1 | 2008 | ||
| 4 | FR | 0.9/0.7 | 1.2±0.0 | |||
| FFPE | 1.0±0.0 | 4.5 | 1.5 | n.a. | ||
| 5 | FR | 0.9/0.7 | 3.5±0.1 | |||
| FFPE | 2.4±0.0 | 6.0 | 2.1 | n.a. | ||
| 6 | FR | 6.5 | 7.0±0.2 | |||
| FFPE | 5.4±0.8 | 4.8 | 1.8 | 2008 | ||
| 7 | FR | BLDd | 1.0±0.1 | |||
| FFPE | 1.6±0.1 | 5.9 | 1.2 | 2007 | ||
| 8 | FR | BLDd | 0.5±0.0 | |||
| FFPE | 0.7±0.1 | 4.1 | 1.2 | 2009 | ||
| 9 | FR | BLDd | BLDe | |||
| FFPE | 0.48 | 3.3 | 1.0 | n.a. | ||
| 10 | FR | BLDd | 0.4±0.0 | |||
| FFPE | 1.0 | 1.4 | 1.4 | n.a. | ||
| 11 | FR | BLDd | BLDe | |||
| FFPE | 0.3±0.0 | 6.5 | 2.1 | n.a. | ||
| 12 | FR | 2.3/8.8 | n.a. | |||
| FFPE-A | 2.6±0.1 | 3.0 | 2.2 | 2004 | ||
| FFPE-B | 3.9±0.0 | 3.8 | 2.2 | 2004 | ||
| 13 | FR | 2.7 | n.a. | |||
| FFPE-A | 2.2±0.0 | 3.9 | 1.3 | 2008 | ||
| FFPE-B | 1.9±0.0 | 5.3 | 2.0 | 2008 | ||
| 14 | FR | BLDd | n.a. | |||
| FFPE-A | 0.3±0.0 | 4.2 | 1.4 | 2008 | ||
| FFPE-B | 0.2±0.0 | 4.2 | 1.8 | 2008 | ||
| 15 | FR | 4.3/8.8 | n.a. | |||
| FFPE-A | 1.6±0.2 | 5.7 | 2.3 | 2008 | ||
| FFPE-B | 1.5±0.1 | 7.2 | 1.7 | 2008 | ||
BLD, Below limit of detection; FR, freshly frozen tissues.
aMicrogram DNA per two 10 µm section cuts.
bSurface area FFPE tissues in paraffin block.
cn.a., not analyzed or year of procurement of FFPE tissue is unknown.
dBLD (1 adduct per 108 DNA bases using 32P-postlabeling method).
eBLD (1 adduct per 109 DNA bases in UPLC-MS/MS3).